Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Inclusion Criteria: * Be willing and able to provide written informed consent for the trial. * Be ≥18 years of age on day of signing informed consent. * Have measurable disease based on the Lugano Criteria. * Phase I: patient must have histologically confirmed R/R NHL or HL (defined by World Health Organization (WHO) criteria). * Expansion phase: patients must have histologically confirmed R/R mature T-cell lymphoma (defined by WHO criteria). * Patient must have received at least two prior lines of therapy prior to enrollment in this study. * Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. * Left Ventricular Ejection Fraction (LVEF) \> 50%. * Demonstrate adequate organ function. All screening labs should be performed within 10 days of treatment initiation. The following treatments are prohibited: (a) Chemotherapy, monoclonal antibody within 4 weeks; (b) radiotherapy within 2 weeks prior to entering the study; (c) systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs; (d) other concurrent investigational agents within 4 weeks prior to entering the study; (e) use of copanlisib or romidepsin within the past 3 months. * Patients that have not recovered from adverse events due to chemotherapy agents administered more than 4 weeks earlier. * Hypersensitivity to copanlisib or romidepsin or any of its excipients. * Patients that received major su…